Categories Uncategorized

Canadian Government to Allow Therapists to Use Psilocybin Mushrooms

Canada’s Health Minister Patter Hajdu recently stated that the country would allow some health-care professionals to both consume and possess psilocybin mushrooms. The aim of this move is to provide a way that health-care professionals can better understand and recognize how to treat the increasing number of patients who have been allowed to use the psychedelic.

This is the health ministry’s first public response to the psilocybin-use pending applications by therapists. Over the summer, the health ministry allowed a limited number of patients to use psilocybin mushrooms as part of their psychotherapy in their end-of-life care. However, ministry of health officials had not, at the time, announced whether they would approve similar requests made by therapists.

The health minister stated that she was happy that Health Canada had awarded exemptions to a number of health-care professionals who wanted to consume and possess psychedelic mushrooms. She explained that while the move may be viewed as controversial by some, the doctors who prescribe this therapy wanted to better comprehend what the treatment felt like and the best ways to use the treatment to help patients who are struggling.

The ministry of health office in Canada has the ability to award exemptions that provide people with immunity from Canada’s controlled substances legislations. More than 12 other exemptions have been awarded since August when Health Canada approved the request of four terminally ill cancer patients to use psilocybin legally in their end-of-life care. Earlier in October, the body gave the green light to a nonterminal patient who wanted approval to be allowed to use psilocybin to remedy unresolved trauma.

TheraPsil is a not-for-profit group dedicated to acquiring legal access to psilocybin therapy for Canadians. The Victoria-based group has backed psilocybin applications of end-of-life care patients as well as helped the patient with trauma mentioned above secure approval for their applications. The therapist exemptions that were approved by Health Canada were applied for therapists by TheraPsil earlier this year.

In a press release released soon after the announcement, TheraPsil noted that 17 health-care professionals had been granted exemptions so far. Additionally, the statement announced that the group was also trying to raise $250,000, which would be used to fund a training program for the practitioners.

TheraPsil CEO Spencer Hawkswell stated that the group was grateful to the Minister of Health Patty Hajdu, adding that training would be required in order to explore the problems of patient access. Training would also be essential to help meet patient demand.

The functional mushrooms market segment is set to grow rapidly, and Rritual Superfoods Inc. is positioning itself to take a pole position in this sector. This company makes premium products that contain adaptogens and various superfoods as well as functional mushrooms.

NOTE TO INVESTORS: The latest news and updates relating to Rritual Superfoods Inc. are available in the company’s newsroom at http://ibn.fm/Rritual

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million…

2 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…

2 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

3 months ago